Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

About NXL104

NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (penicillins, cephalosporins, carbopenems) mediated by beta-lactamase enzymes.

NXL104 is a significant advance, as it is able to inhibit a broader range of beta-lactamases than currently marketed inhibitors. Its spectrum includes class A (including ESBL and KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae and Pseudomonas.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Legislation passed ... a pharmacy provision to help prevent inappropriate prescriptions in ... Protecting the Integrity of Medicare Act (PIMA) of ... Chairman Kevin Brady (R-TX) and Ranking Member ... prescription drug abuse epidemic and implement the right policies, ...
(Date:2/26/2015)... MILFORD, Mass. , Feb. 26, 2015 /PRNewswire/ ... developing novel therapeutics for the treatment of Hepatitis ... announced the closing of a $22 million financing. ... of SB 9200, a novel, broad spectrum antiviral ... molecule nucleic acid hybrid (SMNH) chemistry platform, into ...
(Date:2/26/2015)... , Feb. 26, 2015 The market ... is estimated at 2.4 billion in ... population growth, government insurance, newly insured patients and ... region and will continue to propel demand.  The healthcare ... into the market and interviews with IVD manufacturers ...
Breaking Medicine Technology:PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4
(Date:2/26/2015)... Washington, DC (PRWEB) February 26, 2015 ... “ Dual-Eligibles Initiatives: What’s Working? What’s Not? What’s ... for Medicare-Medicaid dual-eligibles programs to achieve strong outcomes ... What has been happening in the implementation phase ... already have been made? Which ones need to ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 2015 marks ... Dentist” for Dr. David Caggiano! , Orthodontics is ... interests. Combining his background in biomedical engineering, his ... experience as a general dentist allows Dr. Caggiano to ... situations. He was named Orthodontic Products’ Best of ...
(Date:2/26/2015)... Michigan (PRWEB) February 26, 2015 A ... procedures that accomplish two different things—but they can be ... blending a tummy tuck with liposuction, Michigan’s Dr. Pramit ... which he's seen grow in popularity by 50 percent ... Why are more patients seeking to combine the two? ...
(Date:2/26/2015)... 2015 Deep Market Research Report on ... study on the current state of the global ... the Chinese situation. , Major companies included in ... Hu-Friedy, Medisporex, Towne Brothers, Teleflex Medical, Landanger, YDM, ... Equipment, Shuanglu, Changshu Henry Medical Instrument, and Kangqiao ...
(Date:2/26/2015)... Lauderdale, FL (PRWEB) February 26, 2015 Body ... is celebrating ten years of delivering high quality mobile ... Metro, Florida and other regions across the United States. The ... to be a pivotal year as it sets its sights ... and corporate office chair massage services. , “We’ve come a ...
Breaking Medicine News(10 mins):Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 2Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 3Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3
... from back pain, pelvic pressure, frequent urination or abnormal periods, ... growths found in the uterus and can range in size ... larger. Now, there’s an improvement to uterine fibroid embolization -- ... women. ,Hormone therapy can help shrink fibroids, and ...
... lung cancer before it’s in a more advanced stage is ... of a recent study.// While a CT scan can detect ... a cost-effective option. A new study conducted by researchers who ... for high-risk patients. ,The research was part of ...
... among men in the United States -- affecting nearly 200,000 ... new research shows there may be a way to prevent ... drug -- finasteride -- will make a difference in preventing ... for baldness. It works by stopping testosterone’s conversion to DHT ...
... to tobacco smoke. Infant exposure to environmental tobacco smoke ... asthma, and other respiratory conditions. ,A recent study ... of 314 infants living in smoking households. Participating infants ... from the University of Warwick, United Kingdom, found banning ...
... recent study shows only 7 percent of diabetics ... and blood vessel problems. // Researchers stressed continued ... disease including retinopathy, neuropathy, nephropathy, coronary heart disease, ... nearly 1,700 adults, ages 20 years or older, ...
... or water exercise, may improve strength and mobility in patients ... 100 patients with osteoarthritis who were older than age 50. ... three times a week in a swimming pool, the second ... at all. Both the water and gym programs focused on ...
Cached Medicine News:
... first wavefront aberrometer specifically designed to meet ... Practitioner. Utilizing a proprietary, non Hartmann-Shack technology ... accurately measures high order aberrations (3rd-6th order), ... to arrive at a fully optimized prescription ...
... Heidelberg Multi Color (HMC) ... a microprocessor-controlled precision assessment ... the red/green range (Rayleigh ... (Moreland equation) with integrated ...
... Alcons new Infiniti Vision System is ... surgical instrument. This single instrument now ... methods to remove a cataract. The ... and unique tri-modal energy delivery options ...
... MDoffice seamlessly integrates practice management ... and simplify office and clinical ... charting, billing, accounting and reporting ... facilities and specialties. MDoffice immediately ...
Medicine Products: